A carregar...
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
AIM: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. METHODS: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pego...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6386207/ https://ncbi.nlm.nih.gov/pubmed/30858713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S192235 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|